Opthea Limited is a clinical-stage biopharmaceutical company that develops therapies to treat ophthalmic diseases. The company's lead product candidate, OPT-302, is a novel VEGF-C/D 'trap' therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT-302 has shown promising results in Phase 1/2a clinical trials, and Opthea is currently conducting Phase 2b trials for the treatment of wet AMD and DME.
Opthea's approach is unique in that it targets both VEGF-A and VEGF-C/D pathways, which may lead to superior outcomes compared to current standard-of-care treatments for wet AMD and DME that only target VEGF-A. Additionally, Opthea has a preclinical pipeline of therapies for other ophthalmic diseases.
Opthea is headquartered in Melbourne, Australia, and has a U.S. subsidiary based in New York. The company went public on the NASDAQ in 2020 under the ticker symbol OPT.
Opthea Limited is a clinical-stage biopharmaceutical company that develops therapies to treat ophthalmic diseases. The company's lead product candidate, OPT-302, is a novel VEGF-C/D 'trap' therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT-302 has shown promising results in Phase 1/2a clinical trials, and Opthea is currently conducting Phase 2b trials for the treatment of wet AMD and DME.